Research and Markets: Pharmaceutical & Healthcare Annual Deals Analysis 2012
March 15 2012 - 1:58PM
Business Wire
Dublin - Research and Markets
(http://www.researchandmarkets.com/research/c49e9a8e/pharmaceutical_h)
has announced the addition of GlobalData's new report
"Pharmaceutical & Healthcare Annual Deals Analysis 2012" to
their offering.
Pharmaceutical & Healthcare Annual Deals Analysis 2012
report is an essential source of data and trend analysis on
partnerships, licensing, mergers and acquisitions (M&A) and
financing in the pharmaceutical and healthcare market. The report
provides detailed information on Partnerships, Licensing
Agreements, M&As, Equity/Debt Offerings, Private Equity and
Venture Financing transactions registered in the pharmaceutical and
healthcare industry in Q4 2011. The report presents detailed
comparative data on the number of deals and their value in the past
five quarters categorized into deal types, segments, and
geographies. Additionally, the report provides information on the
top venture capital and advisory firms in the pharmaceutical and
healthcare industry.
Deals And Value Of Deals Decline 19% And 14% In The
Pharmaceutical and Healthcare Industry In 2011
The pharmaceutical and healthcare industry recorded a decline of
19% in deals and 14% in deal values, respectively in 2011 with the
companies in the industry reducing their investments in R&D
activities, decline in revenues from sales of drugs due to patent
expiries, and growth in major market stalling. The industry
recorded 4,032 deals worth $298.7 billion in 2011, as compared to
5,011 deals worth $346.9 billion in 2010. The oncology market
recoded 848 deals and stood at the top in the pharmaceutical and
healthcare industry in 2011.
Some of the high value deals in 2011 include, Medco Health
Solutions, Inc., a provider of healthcare services, announcing
acquisition of Express Scripts, a provider of pharmacy benefit
management services, for a consideration of $29.1 billion; Takeda
Pharmaceutical's acquisition of Nycomed International, a
pharmaceutical company, for a purchase consideration of 9,600m
($13,681m) on a cash-free, debt-free basis; and Gilead Sciences'
acquisition of Pharmasset, a clinical-stage pharmaceutical company,
for a purchase consideration of $11,200m.
Key Topics Covered:
1 Table of contents
2 Pharmaceutical & Healthcare, Global, Deals Summary
3 Pharmaceuticals & Healthcare, Global, Top Deal Makers,
2011
4 Pharmaceuticals & Healthcare, Global, Deal Summary, by
Type
5 Pharmaceuticals & Healthcare, Global, Deal Summary, By
Market
6 Pharmaceuticals & Healthcare, Deal Summary, By
Geography
7 Pharmaceuticals & Healthcare, Global, Top Financial
Advisors
8 Further Information
For more information visit
http://www.researchandmarkets.com/research/c49e9a8e/pharmaceutical_h
Source: GlobalData